The research behind L-ergothioneine
In 2018, biochemist Bruce Ames proposed a new category of nutrients in PNAS: "putative longevity vitamins." Ergothioneine was on the list. Here's what the published research actually says.
How we frame "longevity vitamin." We always say "putative longevity vitamin." Putative means proposed — a scientific hedge that Ames included deliberately. The 2018 paper presents a hypothesis, not an established conclusion. We don't claim ergothioneine extends human lifespan. No study has demonstrated that.
The Foundational Paper
Ames (2018) — Prolonging Healthy Aging: Longevity Vitamins and Proteins
Proceedings of the National Academy of Sciences, 2018. DOI: 10.1073/pnas.1809045115.
Bruce Ames — one of the most cited biochemists of the past half-century, known for developing the Ames mutagenicity test and decades of work on DNA damage and nutritional science — proposed a new category: "longevity vitamins." Compounds not immediately essential for survival, but which appear to prevent damage that accumulates over long timescales. Ergothioneine was on his list of candidates.
Why this matters: This single paper changed how the field thinks about ergothioneine. It's the foundational citation for MitoV+ — but always with the "putative" qualifier intact.
Read the full paper on PNAS →Mechanism of Action
Ergothioneine Antioxidant Function (multiple papers)
Foundational mechanism research includes: "The Antioxidant Action of Ergothioneine" (1990); "Ergothioneine — more powerful antioxidant than either coenzyme Q10 and idebenone" (2007); "An Uncommon Redox Behaviour Enlightens Ergothioneine's Antioxidant Properties" (2014); "Ergothioneine Antioxidant Function" (2017).
Why this matters: The mechanistic basis for ergothioneine's "cellular antioxidant resilience" positioning. These are in vitro / cellular characterization studies — strong mechanism evidence, not human outcome evidence.
Distribution and Accumulation of Dietary Ergothioneine in Mouse Tissues (2017)
Pharmacokinetic study in mice showing where dietary ergothioneine ends up in the body.
MitoPrime®-Specific Research (NNB Nutrition)
NNB-001 Lifespan Final Report (C. elegans, 2021)
Provider: InVivo Biosystems (Eugene, OR). Lead Scientist: Dr. Adam Saunders, PhD. Project Code: NNB-001. Date: October 12, 2021. Customer: NNB Nutrition.
Lifespan and healthspan study in Caenorhabditis elegans (a research worm model widely used in aging biology).
Why this matters: The first lifespan study commissioned by the MitoPrime supplier in a real organism. C. elegans is not human — extrapolation requires care — but it's a starting point for the lifespan story Ames hypothesized.
Effect of oral MitoPrime on plasma glutathione in healthy human subjects
Manufacturer human study examining how MitoPrime supplementation affects plasma glutathione (a major endogenous antioxidant).
Why this matters: One of the few human studies in the MitoPrime research portfolio. Manufacturer-sponsored — but at least a real human evaluation.
Safety evaluation of nature-identical L-ergothioneine
Safety / toxicology dossier supporting MitoPrime's use as a dietary supplement ingredient.
Observational Human Research (Critically Caveated)
Smith (2020) — Malmö Diet and Cancer Cohort: ergothioneine and cardiovascular mortality
Observational cohort study from the Malmö Diet and Cancer cohort (Sweden).
What this finding means and doesn't mean. Observational association is not proof that taking ergothioneine supplements reduces cardiovascular risk. The association may reflect dietary patterns associated with high ergothioneine intake (mushroom-rich diets) rather than ergothioneine itself. Supplementation has not been tested for this endpoint in a randomized controlled trial. We never make cardiovascular outcome claims for MitoV+.
Patents
EAN B Manufacturing Technology (PCT international patent)
Filed by NNB Nutrition. Covers proprietary manufacturing technology for ergothioneine.
Methods for Ameliorating Aging
US provisional patent application filed by NNB Nutrition. Methods related to ergothioneine and aging-pathway interventions.
Manufacturing & Quality Assurance
Manufactured in an FDA-registered facility
MitoV+ is manufactured in an FDA-registered, cGMP-compliant facility.
Independent batch testing — FARE Labs Private Limited
Current production batch verified:
- L-ergothioneine per gummy: 4.78 mg (label spec: 5 mg, NLT 90% spec met)
- Heavy metals (As, Pb, Hg, Cd): all below limit of quantification
- Pathogens (E. coli, Salmonella, Staph aureus, Pseudomonas): all absent
- Total aerobic count: <10 cfu/g (spec NMT 1,000)
